Retrospective analysis of cyclosporine A (sandimmun neoral) efficacy and safety in patients with juvenile idiopathic arthritis

Objective. To assess sandimmun neoral (SN) efficacy and safety in pts with juvenile chronic arthritis (JCA). Material and methods. 25 pts (20 girls, 5 boys) aged 3 to 15,5 years (mean 9,7±3,7 years) with JCA were included. 12 from them had systemic and 13 - joint form of the disease. 92% of pts had...

Full description

Saved in:
Bibliographic Details
Main Authors: S O Salugina, N N Kuzniina
Format: Article
Language:Russian
Published: IMA PRESS LLC 2004-08-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/948
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849773726775640064
author S O Salugina
N N Kuzniina
author_facet S O Salugina
N N Kuzniina
author_sort S O Salugina
collection DOAJ
description Objective. To assess sandimmun neoral (SN) efficacy and safety in pts with juvenile chronic arthritis (JCA). Material and methods. 25 pts (20 girls, 5 boys) aged 3 to 15,5 years (mean 9,7±3,7 years) with JCA were included. 12 from them had systemic and 13 - joint form of the disease. 92% of pts had polyarthritis and 8% - oligoarthritis. Mean duration of the disease was 5,22+2,5 years (1,5-9,5 years). SN dose varied from 0,5 to 5 mg/kg/day (mean 2,9±l,l mg/kg/day). Treatment duration ranged from 1 month to 5 years. Results. Good and fair effect was achieved in 48% of pts. Swollen joint count significantly decreased particularly after a year of treatment. Laboratory indices of inflammatory activity did not decrease significantly. In 52% of children response to the treatment was unsatisfactory or absent. Half of the pts (52%) had adverse reactions during the treatment with SN. Blood creatinine level elevation was the most significant (8 pts). The reason for the treatment termination was absence of the effect in 8, creatinine elevation - in 2 and financial problems - in 5 pts. Conclusion. Treatment with SN was effective in half of the pts particularly in joint form of JCA.In the whole drug tolerability was good, while half of the pts had adverse reactions which usually did not required treatment termination.
format Article
id doaj-art-e025d5aa45464ea7b0c6f9c27af77f2e
institution DOAJ
issn 1995-4484
1995-4492
language Russian
publishDate 2004-08-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-e025d5aa45464ea7b0c6f9c27af77f2e2025-08-20T03:01:58ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922004-08-01424899110.14412/1995-4484-2004-811888Retrospective analysis of cyclosporine A (sandimmun neoral) efficacy and safety in patients with juvenile idiopathic arthritisS O SaluginaN N KuzniinaObjective. To assess sandimmun neoral (SN) efficacy and safety in pts with juvenile chronic arthritis (JCA). Material and methods. 25 pts (20 girls, 5 boys) aged 3 to 15,5 years (mean 9,7±3,7 years) with JCA were included. 12 from them had systemic and 13 - joint form of the disease. 92% of pts had polyarthritis and 8% - oligoarthritis. Mean duration of the disease was 5,22+2,5 years (1,5-9,5 years). SN dose varied from 0,5 to 5 mg/kg/day (mean 2,9±l,l mg/kg/day). Treatment duration ranged from 1 month to 5 years. Results. Good and fair effect was achieved in 48% of pts. Swollen joint count significantly decreased particularly after a year of treatment. Laboratory indices of inflammatory activity did not decrease significantly. In 52% of children response to the treatment was unsatisfactory or absent. Half of the pts (52%) had adverse reactions during the treatment with SN. Blood creatinine level elevation was the most significant (8 pts). The reason for the treatment termination was absence of the effect in 8, creatinine elevation - in 2 and financial problems - in 5 pts. Conclusion. Treatment with SN was effective in half of the pts particularly in joint form of JCA.In the whole drug tolerability was good, while half of the pts had adverse reactions which usually did not required treatment termination.https://rsp.mediar-press.net/rsp/article/view/948uvenile chronic arthritissandimmun neoral (cyclosporine)
spellingShingle S O Salugina
N N Kuzniina
Retrospective analysis of cyclosporine A (sandimmun neoral) efficacy and safety in patients with juvenile idiopathic arthritis
Научно-практическая ревматология
uvenile chronic arthritis
sandimmun neoral (cyclosporine)
title Retrospective analysis of cyclosporine A (sandimmun neoral) efficacy and safety in patients with juvenile idiopathic arthritis
title_full Retrospective analysis of cyclosporine A (sandimmun neoral) efficacy and safety in patients with juvenile idiopathic arthritis
title_fullStr Retrospective analysis of cyclosporine A (sandimmun neoral) efficacy and safety in patients with juvenile idiopathic arthritis
title_full_unstemmed Retrospective analysis of cyclosporine A (sandimmun neoral) efficacy and safety in patients with juvenile idiopathic arthritis
title_short Retrospective analysis of cyclosporine A (sandimmun neoral) efficacy and safety in patients with juvenile idiopathic arthritis
title_sort retrospective analysis of cyclosporine a sandimmun neoral efficacy and safety in patients with juvenile idiopathic arthritis
topic uvenile chronic arthritis
sandimmun neoral (cyclosporine)
url https://rsp.mediar-press.net/rsp/article/view/948
work_keys_str_mv AT sosalugina retrospectiveanalysisofcyclosporineasandimmunneoralefficacyandsafetyinpatientswithjuvenileidiopathicarthritis
AT nnkuzniina retrospectiveanalysisofcyclosporineasandimmunneoralefficacyandsafetyinpatientswithjuvenileidiopathicarthritis